ID   MNNG/HOS Cl #5
AC   CVCL_0439
AS   CVCL_3952
SY   MNNG/HOS; MNNG-HOS; HOS-MNNG; HOS/MNNG; MNNGHOS; MNNG-HOS (Cl#5); MNNG/HOS Clone F-5; MNNG; R-1059-D; TE85; Te85; TE-85; HOS-TE85; Hos TE-85; HOS TE 85; HOS TE85; HOS (TE85); HOS(TE85); HOS (TE85, Clone F5); MNNG-HOS (TE 85, clone F-5); TE-85 clone F-5; HOS-Te85; TE 85.T; TE 85 ClF-5; HOS-TE85 clone 5; TE-85 clone 5
DR   BTO; BTO:0005416
DR   CLO; CLO_0003796
DR   CLO; CLO_0007813
DR   CLO; CLO_0007814
DR   EFO; EFO_0002866
DR   MCCL; MCC:0000334
DR   CLDB; cl1703
DR   CLDB; cl1704
DR   CLDB; cl1705
DR   CLDB; cl3510
DR   ATCC; CRL-1547
DR   ATCC; CRL-7734
DR   ATCC; CRL-7735
DR   cancercelllines; CVCL_0439
DR   CCRID; 3101HUMTCHu167
DR   CCRID; 5301HUM-KCB16037YJ
DR   ChEMBL-Cells; CHEMBL3307282
DR   ChEMBL-Targets; CHEMBL614038
DR   CLS; 300289
DR   Cosmic; 1044084
DR   Cosmic; 1074402
DR   Cosmic; 1529901
DR   Cosmic; 2301584
DR   ECACC; 87070201
DR   GEO; GSM879219
DR   GEO; GSM1915008
DR   GEO; GSM1915009
DR   GEO; GSM1915010
DR   GEO; GSM1915011
DR   GEO; GSM1915025
DR   GEO; GSM1915026
DR   GEO; GSM1915027
DR   GEO; GSM1915028
DR   GEO; GSM1915029
DR   GEO; GSM2635307
DR   GEO; GSM2635308
DR   IARC_TP53; 25022
DR   KCB; KCB 2016037YJ
DR   KCLB; 21543
DR   Progenetix; CVCL_0439
DR   PubChem_Cell_line; CVCL_0439
DR   Wikidata; Q54906271
RX   PubMed=265298;
RX   PubMed=833871;
RX   PubMed=1385192;
RX   PubMed=2823272;
RX   PubMed=2978869;
RX   PubMed=3335022;
RX   PubMed=3518877;
RX   PubMed=6254071;
RX   PubMed=6269117;
RX   PubMed=6575958;
RX   PubMed=7873286;
RX   PubMed=12645653;
RX   PubMed=19787792;
RX   PubMed=21519327;
RX   PubMed=22282976;
RX   PubMed=23144859;
RX   PubMed=24136885;
RX   PubMed=26320182;
RX   PubMed=28196595;
RX   PubMed=29334376;
WW   https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC   Population: Caucasian.
CC   Doubling time: ~24 hours (PubMed=21519327).
CC   Selected for resistance to: ChEBI; CHEBI:21759; N-methyl-N'-nitro-N-nitrosoguanidine (MNNG).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19787792).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (PubMed=19787792).
CC   Omics: H3K4me1 ChIP-seq epigenome analysis.
CC   Omics: H3K27ac ChIP-seq epigenome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Misspelling: MNNG/HOSC1#5; CCRID=5301HUM-KCB16037YJ.
CC   Discontinued: ATCC; CRL-7734; true.
CC   Discontinued: ATCC; CRL-7735; true.
CC   Derived from site: In situ; Bone, right femur; UBERON=UBERON_0000981.
ST   Source(s): ATCC; CCRID; CLS; ECACC; KCLB; PubMed=19787792
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 12
ST   D16S539: 10,13
ST   D18S51: 14
ST   D19S433: 13
ST   D21S11: 31.2
ST   D2S1338: 24,25
ST   D3S1358: 15
ST   D5S818: 13
ST   D7S820: 11,12
ST   D8S1179: 11,14 (PubMed=19787792)
ST   D8S1179: 14 (CLS)
ST   FGA: 24
ST   Penta D: 9,10
ST   Penta E: 7,12
ST   SE33: 20,21
ST   TH01: 6
ST   TPOX: 8,11 (ATCC; CCRID; CLS; ECACC; KCLB)
ST   TPOX: 11 (PubMed=19787792)
ST   vWA: 18
DI   NCIt; C9145; Osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0312 ! HOS
SX   Female
AG   13Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 33
//
RX   PubMed=265298; DOI=10.1002/ijc.2910190411;
RA   Rhim J.S., Putman D.L., Arnstein P., Huebner R.J., McAllister R.M.;
RT   "Characterization of human cells transformed in vitro by
RT   N-methyl-N'-nitro-N-nitrosoguanidine.";
RL   Int. J. Cancer 19:505-510(1977).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=1385192; DOI=10.1016/0531-5565(92)90007-m;
RA   Fleming T.P., Matsui T., Aaronson S.A.;
RT   "Platelet-derived growth factor (PDGF) receptor activation in cell
RT   transformation and human malignancy.";
RL   Exp. Gerontol. 27:523-532(1992).
//
RX   PubMed=2823272; DOI=10.1073/pnas.84.21.7716;
RA   Masuda H., Miller C., Koeffler H.P., Battifora H.A., Cline M.J.;
RT   "Rearrangement of the p53 gene in human osteogenic sarcomas.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:7716-7719(1987).
//
RX   PubMed=2978869;
RA   Ehrhart J.-C., Duthu A., Ullrich S., Appella E., May P.;
RT   "Specific interaction between a subset of the p53 protein family and
RT   heat shock proteins hsp72/hsc73 in a human osteosarcoma cell line.";
RL   Oncogene 3:595-603(1988).
//
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=6254071; DOI=10.1073/pnas.77.9.5258;
RA   Todaro G.J., Fryling C.M., De Larco J.E.;
RT   "Transforming growth factors produced by certain human tumor cells:
RT   polypeptides that interact with epidermal growth factor receptors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 77:5258-5262(1980).
//
RX   PubMed=6269117; DOI=10.3181/00379727-167-41221;
RA   Rhim J.S.;
RT   "Characterization of sarcoma-positive, leukemia-negative (S+L-) human
RT   cells induced by the feline leukemia virus pseudotype of Moloney
RT   sarcoma virus.";
RL   Proc. Soc. Exp. Biol. Med. 167:597-606(1981).
//
RX   PubMed=6575958; DOI=10.1007/BF02619599;
RA   Tsang K.-Y., Fudenberg H.H., Sun D.C., Pai G.S., Bishop L.R., Sager S.;
RT   "Cultivation of human osteosarcoma cell lines in serum-free hormone
RT   supplemented medium.";
RL   In Vitro 19:515-521(1983).
//
RX   PubMed=7873286; DOI=10.1016/8756-3282(94)90305-0;
RA   Clover J., Gowen M.;
RT   "Are MG-63 and HOS TE85 human osteosarcoma cell lines representative
RT   models of the osteoblastic phenotype?";
RL   Bone 15:585-591(1994).
//
RX   PubMed=12645653; DOI=10.1016/S0165-4608(02)00685-4;
RA   Ozaki T., Neumann T., Wai D.H., Schaefer K.-L., van Valen F., Lindner N.,
RA   Scheel C., Boecker W., Winkelmann W., Dockhorn-Dworniczak B., Horst J.,
RA   Poremba C.;
RT   "Chromosomal alterations in osteosarcoma cell lines revealed by
RT   comparative genomic hybridization and multicolor karyotyping.";
RL   Cancer Genet. Cytogenet. 140:145-152(2003).
//
RX   PubMed=19787792; DOI=10.1002/gcc.20717;
RA   Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S.E.,
RA   Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H.,
RA   Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W.,
RA   Buerger H., Aigner T., Gabbert H.E., Poremba C.;
RT   "Molecular characterization of commonly used cell lines for bone tumor
RT   research: a trans-European EuroBoNet effort.";
RL   Genes Chromosomes Cancer 49:40-51(2010).
//
RX   PubMed=21519327; DOI=10.1038/labinvest.2011.72;
RA   Mohseny A.B., Machado I., Cai Y.-P., Schaefer K.-L., Serra M.,
RA   Hogendoorn P.C.W., Llombart-Bosch A., Cleton-Jansen A.-M.;
RT   "Functional characterization of osteosarcoma cell lines provides
RT   representative models to study the human disease.";
RL   Lab. Invest. 91:1195-1205(2011).
//
RX   PubMed=22282976; DOI=10.1093/carcin/1.1.21;
RA   Day R.S. III, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A.,
RA   Mattern M.R.;
RT   "Human tumor cell strains defective in the repair of alkylation
RT   damage.";
RL   Carcinogenesis 1:21-32(1980).
//
RX   PubMed=23144859; DOI=10.1371/journal.pone.0048262;
RA   Kresse S.H., Rydbeck H., Skarn M., Namlos H.M., Barragan-Polania A.H.,
RA   Cleton-Jansen A.-M., Serra M., Liestol K., Hogendoorn P.C.W., Hovig E.,
RA   Myklebost O., Meza-Zepeda L.A.;
RT   "Integrative analysis reveals relationships of genetic and epigenetic
RT   alterations in osteosarcoma.";
RL   PLoS ONE 7:E48262-E48262(2012).
//
RX   PubMed=24136885; DOI=10.1002/pbc.24801;
RA   Guma S.R., Lee D.A., Yu L., Gordon N., Hughes D., Stewart J.,
RA   Wang W.-L., Kleinerman E.S.;
RT   "Natural killer cell therapy and aerosol interleukin-2 for the
RT   treatment of osteosarcoma lung metastasis.";
RL   Pediatr. Blood Cancer 61:618-626(2014).
//
RX   PubMed=26320182; DOI=10.18632/oncotarget.5177;
RA   Ren L., Mendoza A., Zhu J., Briggs J.W., Halsey C., Hong E.S.,
RA   Burkett S.S., Morrow J.J., Lizardo M.M., Osborne T., Li S.Q.,
RA   Luu H.H., Meltzer P.S., Khanna C.;
RT   "Characterization of the metastatic phenotype of a panel of
RT   established osteosarcoma cells.";
RL   Oncotarget 6:29469-29481(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29334376; DOI=10.1038/nm.4475;
RA   Morrow J.J., Bayles I., Funnell A.P.W., Miller T.E., Saiakhova A.,
RA   Lizardo M.M., Bartels C.F., Kapteijn M.Y., Hung S., Mendoza A.,
RA   Dhillon G., Chee D.R., Myers J.T., Allen F., Gambarotti M., Righi A.,
RA   DiFeo A., Rubin B.P., Huang A.Y., Meltzer P.S., Helman L.J., Picci P.,
RA   Versteeg H., Stamatoyannopoulos J.A., Khanna C., Scacheri P.C.;
RT   "Positively selected enhancer elements endow osteosarcoma cells with
RT   metastatic competence.";
RL   Nat. Med. 24:176-185(2018).
//